Chronic Lymphocytic Leukemia (CLL)
Conditions
Brief summary
This is a phase 2, open-label, single institution trial of combination of intravenous (IV) ofatumumab and oral GSK2110183 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). Patients must have received at least one prior line of therapy containing fludarabine (single-agent or combination therapy). During the initial 6 months Treatment Phase, ofatumumab will be administered weekly for 8 doses, then once every 4 week cycle for an additional 4 doses (dose and schedule identical to the pivotal phase 2 trial) and GSK2110183 will be given daily PO (Treatment Phase). There will be an initial 10 day lead-in with GSK2110183 alone prior to initiation of ofatumumab to allow for evaluation of changes in cell surface expression due to GSK2110183 and for GSK2110183 pharmacokinetic studies (Lead-in Phase). The official Cycle 1 Day 1 will start on the date of first dose of ofatumumab. Cycle duration = 4 weeks. Patients will be assessed for safety, disease assessment, response, and survival on day 1 of each cycle during the Treatment Phase. A formal review of safety data by the Data Safety Monitoring Board (DSMB) after the first 6 patients have completed cycle 1 of the Treatment Phase will be performed before continuing accrual. All patients achieving SD, PR or CR by the end of the Treatment Phase will proceed to the Maintenance Phase. Patients with PD at any time, including by the end of Treatment Phase, will be taken off study. During the Maintenance Phase, single-agent GSK2110183 will be administered daily for a maximum of 12 months (12 cycles). Maximum duration on any study drug is 18 months (18 cycles). During the Follow-up Phase, patients will be assessed for safety, disease assessment, response, and survival every 3 months through month 36 (year 3), or until subsequent CLL therapy or death, whichever comes first. Key indications for study withdrawal are progressive disease, intolerable toxicity, or completion of therapy
Interventions
DRUGOfatumumab with GSK2110183
* GSK2110183 125mg OD continuously * Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses
Sponsors
Novartis
University Health Network, Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must fulfill all of the following criteria to be eligible for admission to the study: * A confirmed diagnosis of B-cell CLL by IWCLL 2008 criteria (Appendix 1) * Patients must have evidence of disease progression as evidenced by rapid doubling of peripheral lymphocyte count, progressive lymphadenopathy or hepatosplenomegaly, worsening anemia or thrombocytopenia, or progressive constitutional symptoms \[including fatigue, weight loss, night sweats, fever (without infection)\] * Must be relapsed or refractory to at least one prior fludarabine-containing regimen (no maximum number of prior regimens). * Age \> 18 years. * ECOG performance status of 0, 1 or 2 (Appendix 3) * Signed the Informed Consent form * Life expectancy of ≥ 6 months * Able to swallow and retain oral medication * Normal HbA1C ≤ 0.07 * Fasting blood sugar \< 7mmol/L
Exclusion criteria
* Subjects meeting any of the following criteria are excluded from this study: * CLL therapy, including stem cell transplantation, within 4 weeks of study initiation. Corticosteroids alone may be administered up to seven days prior to the first dose of study drug. * Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study * Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy * Known hypersensitivity to ofatumumab, GSK2110183, or any components therein. * Anticoagulants are permitted only if the subject meets PTT and INR entry criteria (INR and PTT ≤ 1.5 times upper normal limit). Their use must be monitored in accordance with local institutional practice. * Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other than aspirin (81mg daily). * Current use of a prohibited medication based on potential drug-drug interaction - a complete list is found in Appendix 1 * Known CNS involvement with CLL * Transformation to aggressive B-cell malignancy (e.g. large B-cell lymphoma, Richter's syndrome, prolymphocytic leukemia \[PLL\]) * Active autoimmune disease - prior history of autoimmune hemolysis (DAT positive or negative) or immune thrombocytopenia without current active autoimmune disease is allowed * Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable non-hepatitis B or C chronic liver disease per investigator assessment - please see below for Hepatitis B and C criteria) * Previously diagnosed diabetes mellitus (Type 1 or 2) * Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible. * Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, and tuberculosis. * Any medical condition that would require long-term use (\> 1 month) of systemic corticosteroids during study treatment (excludes topical or inhaled corticosteroid use) * History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae * QTc ≥ 470 msec on screening ECG * Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to study entry, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities. * Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient. * Any major surgery within the prior 4 weeks. * Known HIV positive * Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded. * Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result * Screening laboratory values: platelets ≤ 30 x 109/L,neutrophils ≤ 0.7 x 109/L,creatinine ≥ 2.0 times upper normal limit, total bilirubin ≥ 1.5 times upper normal limit (unless due to a known history of Gilbert's disease), ALT ≥ 2.5 times upper normal limit, alkaline phosphatase ≥ 2.5 times upper normal limit, INR and PTT ≤ 1.5 times upper normal limit * Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening. * Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as intrauterine device, double barrier method or total abstinence. Oral contraceptives are not adequate due to potential drug-drug interaction. * Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate, as Per the IWCLL 2008 Response Criteria | 36 months | IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes \< 4 x 109/L, absence of significant lymphadenopathy (\>1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): ≥ 50% decrease in the peripheral blood lymphocytes from baseline, \> 50% reduction in the sum products of up to 6 lymph nodes, \> 50% reduction in hepatomegaly and/or neutrophils \> 1.5 x109/L, platelets \> 100 x109/L, hemoglobin \> 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, \> 50% increase in the absolute number of circulating lymphocytes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | 36 months | — |
| Median Progression Free Survival, Overall Survival | 36 months | Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause. Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause. |
| Median Duration of Response | 36 months | Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles. |
Countries
Canada
Participant flow
Recruitment details
Study enrollment was stopped as of 13 Sep 2016. 28 patients were enrolled. Data analysis is complete and manuscript has been being submitted.
Participants by arm
| Arm | Count |
|---|---|
| Ofatumumab With GSK2110183 Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
\- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses | 28 |
| Total | 28 |
Baseline characteristics
| Characteristic | Ofatumumab With GSK2110183 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 13 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 26 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 26 Participants |
| Region of Enrollment Canada | 28 participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 27 / 27 |
| other Total, other adverse events | 27 / 27 |
| serious Total, serious adverse events | 14 / 27 |
Outcome results
Primary
Overall Response Rate, as Per the IWCLL 2008 Response Criteria
IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes \< 4 x 109/L, absence of significant lymphadenopathy (\>1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): ≥ 50% decrease in the peripheral blood lymphocytes from baseline, \> 50% reduction in the sum products of up to 6 lymph nodes, \> 50% reduction in hepatomegaly and/or neutrophils \> 1.5 x109/L, platelets \> 100 x109/L, hemoglobin \> 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, \> 50% increase in the absolute number of circulating lymphocytes
Time frame: 36 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ofatumumab With GSK2110183 | Overall Response Rate, as Per the IWCLL 2008 Response Criteria | Complete response | 1 Participants |
| Ofatumumab With GSK2110183 | Overall Response Rate, as Per the IWCLL 2008 Response Criteria | Partial response | 13 Participants |
| Ofatumumab With GSK2110183 | Overall Response Rate, as Per the IWCLL 2008 Response Criteria | Stable disease | 14 Participants |
Secondary
Median Duration of Response
Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles.
Time frame: 36 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ofatumumab With GSK2110183 | Median Duration of Response | 6.4 months |
Secondary
Median Progression Free Survival, Overall Survival
Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause. Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause.
Time frame: 36 months
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Ofatumumab With GSK2110183 | Median Progression Free Survival, Overall Survival | Median PFS time (months) | 8.5 months |
| Ofatumumab With GSK2110183 | Median Progression Free Survival, Overall Survival | 1 year overall survival time (months) | 88.3 months |
| Ofatumumab With GSK2110183 | Median Progression Free Survival, Overall Survival | 2 year overall survival time | 68.1 months |
Secondary
Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03)
Time frame: 36 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Upper respiratory infections (%) | 71 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Skin (%) | 32 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Response rate (%) | 50 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Stable Disease (%) | 50 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Upper respiratory Infections (%) | 71 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Cough (%) | 64 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Diarrhea (%) | 61 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Dyspnea (%) | 36 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Lung Infections (%) | 18 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Urinary tract infection (%) | 18 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Neutropenia Grade 3-4(%) | 39 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Thrombocytopenia Grade 3-4 (%) | 32 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Anemia Grade 3-4 (%) | 25 percentage of participants |
| Ofatumumab With GSK2110183 | Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03) | Infusion related reactions (%) | 75 percentage of participants |